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Abstract
Purpose The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced NSCLC, leading to a
string of approvals in recent years. Herein, a narrative review on the role of 18F-fluorodeoxyglucose positron emission tomog-
raphy/computed tomography (FDG PET/CT) in the ever-evolving treatment landscape of advanced NSCLC is presented.
Methods This comprehensive review will begin with an introduction into current treatment paradigms incorporating ICIs; the evolu-
tion of CT-based criteria; moving onto novel phenomena observed with ICIs and the current state of hybrid imaging for diagnosis,
treatment planning, evaluation of treatment efficacy and toxicity in advanced NSCLC, also taking into consideration its limitations and
future directions.
Conclusions The advent of ICIs marks the dawn of a new era bringing forth new challenges particularly vis-à-vis treatment
response assessment and observation of novel phenomena accompanied by novel systemic side effects. While FDG PET/CT is
widely adopted for tumor volume delineation in locally advanced disease, response assessment to immunotherapy based on
current criteria is of high clinical value but has its inherent limitations. In recent years, modifications of established (PET)/CT
criteria have been proposed to provide more refined approaches towards response evaluation. Not only a comprehensive
inclusion of PET-based response criteria in prospective randomized controlled trials, but also a general harmonization within
the variety of PET-based response criteria is pertinent to strengthen clinical implementation and widespread use of hybrid
imaging for response assessment in NSCLC.
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Introduction
Intrinsic genomic instability in non-small cell lung cancer
(NSCLC) has facilitated resistance to cytotoxic or targeted
therapies. The advent of immune checkpoint inhibitors
(ICIs) has revolutionized the treatment of advanced/metastatic
NSCLC.
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Immune checkpoints are inhibitory pathways that are per-
tinent to self-tolerance. Tumors confer immune resistance by
interference with these pathways. As a means of counterpoise,
ICIs which act by inhibiting these specific inhibitory immune
checkpoints were developed. Agents targeting cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) [ipilimumab]
and programmed cell death receptor 1 (PD-1) (nivolumab,
pembrolizumab) or its ligand programmed cell death ligand
1 (PD-L1) [durvalumab, atezolizumab] have been approved
for treatment of advancedNSCLC [1]. This marks the dawn of
a new era bringing forth new challenges vis-à-vis treatment
response assessment with observation of novel phenomena
due to their mechanism of action. These patterns of response
include durable response, hyperprogression, pseudo-progres-
sion, and dissociated response possibly amenable to local ab-
lative therapies [2]. Moreover, new patterns of systemic side
effects, i.e., immune-related adverse events (irAEs), are ac-
companying these therapeutic effects. However, only a small
proportion of patients actually respond to treatment with ICIs
[3]. The assessment of PD-L1 expression—despite its inher-
ent limitations—is widely regarded as the best available pre-
dictive biological biomarker and the search for more robust
biomarkers remains an area of intensive research [4]. Over the
years, there has been increased interest in molecular imaging,
particularly 18F-fluorodeoxyglucose positron emission to-
mography/computed tomography (FDG PET/CT) as a tool
for response assessment and prognostication beyond the mere
morphological assessment using CT and MRI [5].
In recent years, a number of groups have proposed modi-
fication of current criteria to more robustly assess response to
these novel agents. In 2019, the EANM (European
Association of Nuclear Medicine) published a consensus re-
port addressing this issue [6]. Herein, we highlight the current
state, limitations, and future directions of hybrid imaging for
treatment planning, evaluation of multimodal treatment effi-
cacy and toxicity in inoperable locally advanced and metasta-
tic NSCLC.
Current multimodal treatment strategy
Inoperable locally advanced (stage III) disease
Radiotherapy is a fundamental pillar of cancer therapy and has
been demonstrated to induce both local and systemic immune
responses. Briefly, irradiation triggers the release of damage-
associated molecular patterns (DAMPs) that can promote an
immunogenic response, described as in situ vaccination [7]. In
inoperable stage III NSCLC, curative-intent platinum-based
chemoradiotherapy (CRT) followed by consolidation ICI with
the PD-L1 inhibitor durvalumab is the new standard of care
(SoC) [8]. Furthermore, there are a plethora of studies
currently assessing this tri-modal treatment paradigm in the
concurrent or sequential setting [9].
Metastatic (stage IV) disease
In the metastatic setting, pre-clinical studies and case reports
have demonstrated a phenomenon whereby shrinkage of un-
treated tumors occurs concurrently with shrinkage of tumors
receiving localized radiotherapy, a phenomenon described as
the “abscopal effect” [10–13]. In addition, in the oligo-meta-
static setting, patients on systemic treatment (including ICIs)
might be amenable to local ablative/consolidative therapies
[14, 15].
Nivolumab was the first ICI approved by the US Food and
Drug Administration (FDA) in 2015 for advanced or metasta-
tic (m)NSCLC in the second-line setting. Later that year,
pembrolizumab was granted accelerated approval in the sec-
ond line. Atezolizumab was also added to the repertoire in the
second-line setting for PD-L1 unselected patients with or
without epidermal growth factor receptor (EGFR) or anaplas-
tic lymphoma kinase (ALK) alterations the following year,
and shortly after, pembrolizumab was the first drug approved
in the first-line treatment for non-oncogene addicted patients
with PD-L1 tumor proportion score (TPS) ≥ 50% and expan-
sion of this indication in 2019 to include patients with PD-L1
positive tumors based on the KEYNOTE-042 trial [1].
PD-L1 expression can either be constitutive or induced in
many tumors to promote cancer immune evasion. In an at-
tempt to combat this adaptive immune resistance, combina-
tions with chemotherapy and anti-angiogenic agents have also
received FDA approval [1]. The latest addition to this set of
therapeutics is nivolumab plus ipilimumab (approved on May
15, 2020 for first-line treatment of non-oncogene addicted
PD-L1 positive metastatic/recurrent NSCLC), atezolizumab
monotherapy (approved on May 18, 2020 in the first-line for
mNSCLC with PD-L1 ≥ 50% of tumor cells or PD-L1 tumor-
infiltrating immune cells covering ≥ 10% of the tumor area
and no EGFR or ALK genomic tumor aberrations), and
nivolumab/ipilimumab plus 2 cycles of platinum-doublet che-
motherapy (approved on May 26, 2020 for the first-line treat-
ment of non-oncogene addicted metastatic/recurrent NSCLC
irrespective of histology and PD-L1 expression based on the
results of CheckMate 9LA) [16–18].
Imaging in NSCLC
Standard conventional imaging
Historically, in an attempt to standardize response assessment
in oncological patients, the World Health Organization
(WHO) initially published recommendations in the 1979
WHO Handbook and sanctioned a publication by Miller et
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al. in 1981, ultimately evaluating response assessment based
on bi-dimensional tumor measurements [19]. However, the
WHO criteria had some major caveats in that the number of
measurable lesions and minimum measurable size of lesions
were not adequately defined.
Two decades later, joint CT-based criteria by the
“European Organization for Research and Treatment of
Cancer” (EORTC) and National Cancer Institute (NCI) were
published—Response Evaluation Criteria in Solid Tumors”
(RECIST). The RECIST criteria proposed a uni-dimensional
(measurement of longest tumor diameter) model integrating a
combined assessment of all existing lesions, characterized by
target lesions and non-target lesions [20]. A revised version
RECIST 1.1 ensued in 2009 and currently represents the gold
standard in CT-based assessment with the majority of (C)RT/
ICI clinical trials evaluating response based on these criteria
[21].
Clinical response patterns to immunotherapy are more
complex than those to cytotoxic or targeted agents. Hence in
2009, immune-related response criteria (irRC) were the pre-
mier novel immune therapy criteria proposed to cover addi-
tional patterns of response observed with these agents and was
based on bi-dimensional measurements [22]. Refinement led
to additional immune-related criteria, namely, immune-related
RECIST (irRECIST), effectively adapted from RECIST and
based on uni-dimensional measurements, proven superior to
irRC [23, 24]. Thereafter, in an attempt to promote congru-
ence, the RECIST working group proposed a consensus
guideline—immune RECIST (iRECIST) based on RECIST
1.1 [25], and finally in 2018, the immune-modified RECIST
(imRECIST) criteria designed to better encapsulate response
to immunotherapy were proposed [26]. A summary of avail-
able CT-based criteria is presented in Table 1, see also analo-
gously (Citation Reference [27]).
Novel phenomena of response to ICIs
Owing to their mechanism of action, ICIs have demonstrated
novel patterns of response [2]. Briefly, the following phenom-
ena have been observed.
Durable response
In the first instance, in heavily pretreated patients with ad-
vanced NSCLC receiving nivolumab for up to 96 weeks, the
estimated 5-year OS rate was 16%, despite nivolumab discon-
tinuation after a maximum of 96 weeks [28]. This is an inter-
esting observation and poses the relevant question of frequen-
cy and duration of ICI treatment also from a cost-effectiveness
and health economics standpoint and remains a topic of in-
tense investigation.
Pseudo-progression
A phenomenon is characterized by a temporary increase in
tumor burden, possibly due to transient immune-cell infiltrate,
therapy-related necrosis, and edema followed by tumor re-
gression. In NSCLC, rates of up to 7% have previously been
described. This poses a major challenge, since the risk of
misinterpreting treatment response based only on size
(RECIST/WHO criteria) is high [19, 21, 29]. The additional
application of FDG PET providing functional information
would suggest improved differentiation between pseudo-
and true progression. However, due to the complexity of the
tumor microenvironment and involved stromal cells, en-
hanced FDG uptake could still mimic an aggregation of pro-
liferating tumor cells similar to an elevated uptake seen
post-(chemo-)radiotherapy and representing an influx of in-
flammatory cells. Indeed modified PET criteria were recently
published and demonstrated a decent ability in predicting clin-
ical outcome and are described in more detail below [30].
Nevertheless, due to rarity of this phenomenon, while
discontinuing treatment might be detrimental, more often than
not true progression is the case.
Hyperprogression
In contrast, hyperprogression is characterized by acceleration
of disease. In a French multicenter retrospective study,
hyperprogressive disease was observed in pretreated patients
with advanced NSCLC who received PD-1/PD-L1 inhibitors
or single agent chemotherapy in 13.8% and 5.1%, respectively
[31]. More recently, different definitions for hyperprogressive
disease were assessed in a pooled retrospective trial with the
authors determining that the 5 definitions assessed did not
characterize the same tumoral behavior with incidences rang-
ing from 5.4–18.5%. A novel definition characterized by the
difference between tumor growth rate pre- and during therapy
> 100 was proposed [32]. Further validation is required and
utility of FDG PET in this scenario warrants further
investigation.
Dissociated response
Another observed phenomenon is the concurrent growth and
regression of different lesions corresponding to mixed re-
sponse seen under chemotherapy or targeted therapies. In a
monocentric study of advanced NSCLC patients treated with
PD-1/PD-L1 inhibitors, dissociated response occurred in 8%
of the cohort and was associated with improved survival in
comparison to patients with true progression [33]. These pro-
gressive lesions are potentially amenable to local ablative ther-
apies with potential induction of “the abscopal effect” in pa-
tients treated with radiotherapy.
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PET imaging in advanced NSCLC
PET in NSCLC diagnosis
FDG PET/CT is recommended as the first-line staging modal-
ity especially in potentially curable NSCLC due to its excel-
lent diagnostic accuracy [34]. It combines the strength of
FDG-PET to visualize cells with an elevated glycolytic rate,
which is an important hallmark of cancer cells, and the high
spatial resolution of the CT. The high negative predictive val-
ue for detection of (thoracic lymph node metastases) has a
major impact on initial patient management [35].
The field of radiogenomics is an emerging area of interest.
Several studies have demonstrated a favorable performance of
PET/CT radiomic features in predicting mutational status
[36–38].
PET for treatment planning in curative-intent locally
advanced (LA)-NSCLC
The largest prospective multicenter study to date was recently
published assessing the role of FDG PET/CT for tumor vol-
ume delineation (TVD) in patients with inoperable LA-
NSCLC undergoing CRT. In the study, PET-alone TVD po-
tentially improved local control without compromising toxic-
ity thus corroborating the lack of additional benefit with elec-
tive nodal irradiation observed in previous smaller trials [39].
Emphasizing the role of PET-based dose escalation, toxic-
ity data of a randomized phase II European study, the PET-
boost trial was published last year [40]. Patients with stage II/
III NSCLC were randomized and treated with an isotoxic
simultaneous integrated boost (SIB) ≥ 72 in 24 daily fractions
Gy to the planning target volume (PTV) of the entire primary
tumor (arm A: 54 patients) vs. only to the regions within the
PTV with an SUVmax ≥ 50% on pretreatment FDG PET/CT
(arm B: 53 patients). Due to slow accrual, the trial was termi-
nated early after randomization of 107 patients (target: 164).
Seventeen deaths with 13 possibly treatment related occurred
in the cohort of 107 patients [40]. In addition, results of the
primary endpoint of 1-year freedom from local failure (FFLF)
and secondary endpoint of overall survival were presented at
the European Society for Radiotherapy and Oncology virtual
meeting 2020 (28 November 2020 - 01 December 2020): at a
median follow-up of 12.6 months, 1-yr FFLF rates were 97%
in arm A and 91% in arm B; 1-/3-year overall survival (OS)
rates were 77%/37% in arm A and 62%/33% in arm B [41]. In
another non-randomized phase II study adopting a different
strategy, mid-treatment PET-based TVD was feasible and as-
sociated with favorable loco-regional tumor control in patients
receiving (C)RT for inoperable stage II/III disease [42] and is
currently being assessed in a randomized manner in the
Radiation Therapy Oncology Group (RTOG) 1106/ACRIN
6697 trial (NCT01507428). Also, the results of this trial
were recently presented at the 2020 virtual World
Conference on Lung Cancer (28-31 January 2021): a total of
138 stage III patients were randomized 1:2 to a standard 60-
Gy arm vs. an adaptive arm delivered in 30 daily fractions.
The primary endpoint was 2-year local-regional control rate.
Median prescription dose was 71 Gy in the adaptive arm. No
significant difference in grade ≥ 3 radiotherapy-induced
toxicity was noted. The overall 2-year local-regional tumor
progression-free time was 27.5 vs. 28.4 months in
the standard and adaptive arm, respectively. This study
demonstrated safety and feasibility of PET-based dose
escalation in stage III disease (published abstract not yet
available).
PET for treatment planning in metastatic NSCLC
Stereotactic ablative radiotherapy (SABR) in combination
with a highly tumor-selective immunocytokine—a form of
interleukin 2 (IL2), namely, L19-IL2: a substance consisting
of the single-chain (scFv) tumor-specific human antibody L19
targeting extra-domain B (ED-B) explicitly (anti-ED-B scFv
L19) coupled to IL2 demonstrated some promising results in a
phase I trial in the absence of any severe (grade ≥ 3) toxicity
(NCT02086721). The results have been proven sufficiently
robust to support progression to a randomized phase II
study—ImmunoSABR: an open-label, multicenter, random-
ized controlled phase II trial assessing SoC treatment (includ-
ing ICI) vs. SoC plus SABR/L19-IL2 in limited metastatic
NSCLC. Importantly all participants will undergo FDG
PET/CT before randomization and contrast-enhanced CT-
scans on follow-up. Hence, PET/CT with its superior diagnos-
tic accuracy will more accurately filter out patients that do not
meet the inclusion criteria (stage IV disease and a max. of 10
metastases) and enable better stratification of oligo- (max. 5
metastases) vs. poly-metastatic (6–10 metastases) disease.
Response assessment will be performed per blinded radio-
logical review for every scan and assessed per RECIST 1.1
and exploratory iRECIST. The primary endpoint of the study
is progression-free survival (PFS) at 1.5 years and exploratory
endpoints will include radiomics analysis (hypoxia status, re-
sponse prediction) and response assessment per iRECIST.
This will certainly provide valuable insights in validation of
this criterion [43].
PET for prediction of outcome in advanced NSCLC
Pre-treatment FDG-PET parameters have been demonstrated
as reliable prognostic factors for outcome and survival. While
SUVmax is mostly used for assessment of treatment response,
metabolic tumor volume (MTV), total MTV (TMTV), and
total lesion glycolysis (TLG) are considered to be the strongest
prognosticators at initial staging. Several studies have shown
the association of these parameters with outcome [44, 45]. An
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association of TMTV and inflammatory status with poor out-
come and lack of durable clinical benefit (DCB) has been
described [44]. In another study, radiomic features from base-
line pre-treatment FDG PET/CT could reliably identify pa-
tients most likely to achieve a DCB [46]. However, it has to
be stated that there is no widespread and uniform application
of these parameters in clinical routine.
PET for response assessment to (C)RT
The changes in metabolic activity following (C)RT can be
observed earlier than morphologic changes on CT-scans and
metabolic changes characterized by PET-metrics (SUVmax;
MTV; TLG) during or shortly after treatment have been iden-
tified as prognostic biomarkers for disease recurrence and sur-
vival [47–55]. An association of residual MTV at a cutoff of
25cm3 with tumor local control was identified [52] and cor-
roboration of these findings in addition to the prognostic role
of pre-treatment primary tumor (PT)-MTV, reduction in mid-
to post-PT-MTV, and an association between post-treatment
PT-MTV and outcome has been previously published [49,
50]. Furthermore, with regard to the role of primary tumor
vs. lymph node metastases metrics, van Diessen et al. detected
an association and superiority of post-treatment primary tumor
PET-metrics compared to lymph node metrics in predicting
outcome [54]. An exemplary patient can be seen in Fig. 1.
PET for response assessment to immunotherapy
Back in 1999, there were first attempts to standardize PET-
based response assessment in oncological imaging; the
EORTC firstly used standardized metabolic information in
specified criteria for the response assessment of oncological
diseases in general [56]. Of note, the EORTC criteria were
also the first PET-based criteria to be applied for monitoring
of immunotherapy [57]. These criteria were then refined with
proposal of the “PET Response Criteria in Solid Tumors”
(PERCIST 1.0) criteria published by Wahl et al. in 2009
[58]. The major novelty of these criteria was the introduction
of SUL (i.e., standardized uptake value [SUV] corrected for
the lean body mass) as an imaging parameter. Here, tumor
SUL 1.5-fold higher than the SUL of the non-affected liver
was set as a prerequisite for an evaluable lesion and assessed
within a spherical volume of interest in the lesion with the
most intense uptake.
Along with the rise of immunotherapeutic agents, these
PET-based criteria however had to be refined as well, in order
to adapt to the new clinical phenomena that accompanied
immunotherapeutic agents. Therefore, Cho et al. prospective-
ly compared different response criteria (i.e., RECIST 1.1,
irRC, EORTC, and PERCIST 1.0) in a rather small set of
patients undergoing immunotherapy in order to derive and
evaluate an optimized set of parameters comprising morpho-
logical and metabolic response parameters on PET/CT during
immunotherapy. The best combination of both morphological
and functional parameters was subsequently summated into
new criteria “PET/CT Criteria for Early Prediction of
Response to Immune Checkpoint Inhibitor Therapy”
(PECRIT) [59].
Additional criteria for response assessment to immunother-
apy were suggested by the Heidelberg group. After evaluating
the pattern of response in melanoma patients, the “PET
Response Evaluation Criteria for Immunotherapy”
(PERCIMT) were established, which take into account the
clinical relevance of the absolute number of new lesions dur-
ing immunotherapy as a definite prerequisite for defining pro-
gression rather than a mere increase of PET-based parameters
[60, 61].
Most recently, immunotherapy adopted PERCIST criteria,
i.e., iPERCIST, were proposed. Of note, these criteria were
derived from a set of patients with advanced NSCLC under-
going nivolumab therapy. Here, a modification of the
PERCIST criteria with features of iRECIST criteria demon-
strated a good stratification of patients with improved clinical
outcome; vice versa, therapy failure was also better captured
[30]. In sum, the term unconfirmed progressive metabolic
disease (UPMD) was introduced; in case of UPMD, an addi-
tional PET/CT scan is needed leading either to the classifica-
tion of confirmed progressive metabolic disease (CPMD) or to
Fig. 1 Treatment response assessment in a 51-year-old patient with
NSCLC cT3 N2 M0 (TNM 8th edition). Following definitive chemora-
diation to a total dose of 63.6 Gy and concomitant cisplatin/vinorelbine,
consolidation with durvalumab was initiated. Previous CT-staging scans
were suggestive of post-treatment and treatment-related changes in the
right upper lobe; 17 months after therapy initiation, FDG PET/CT, how-
ever, revealed a tumor recurrence with highly elevated tumor metabolism
which was later confirmed by histopathology
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omission of UPMD in case of subsequent metabolic response
to immunotherapy [30].
To summarize, several novel criteria for response assess-
ment based on PET-imaging have been proposed and further
refined with special emphasis on clinical phenomena that ac-
company immunotherapy. However, these criteria have to be
incorporated into randomized, clinical trials to confirm their
final validity in prospective settings and comprehensively fos-
ter wide-spread use of hybrid imaging (see Table 2), see also
analogously (Citation Reference [27]).
Taking a closer look at current clinical trials, in a study
including 72 patients with advanced pretreated NSCLC on
nivolumab, an additional prognostic value of metabolic re-
sponse assessment was postulated, potentially aiding treat-
ment decision-making [62]. In another study, changes of
FDG-uptake in terms of PERCIST criteria (compared to the
morphological changes on RECIST 1.1 criteria) were predic-
tive of treatment efficacy even at an early stage of 1 month
after initiation of nivolumab in NSCLC patients; this feature
was also shown to be an independent prognostic factor in
multivariate analysis [63]. Also, response on FDG PET (using
EORTC criteria) in NSCLC patients undergoing atezolizumab
therapy 6 weeks after initiation was predictive of further dis-
ease course [64]. Additionally, FDG PET imaging as follow-
up in patients classified as progressive disease (PD) per
PERCIST criteria identified patients with pseudo-progression
and immune dissociated-response in more than half of patients
previously classified as PD; a significantly improved clinical
outcome was observed in these patients [65].
Interestingly, a recent abstract presented at the 2020
American Society of Clinical Oncology meeting assessed
the role of residual metabolic volume in patients receiving
CRT vs. CRT + ICI and only found a prognostic role of
residual PT-MTV in the CRT cohort [66]. An exemplary case
is displayed in Fig. 2.
Hence, additional functional imaging associated with a
higher resolution for potential patient stratification into differ-
ent prognostic groups helps define patients who might benefit
from treatment modification or intensification. Please refer for
more detailed literature [27].
PET for imaging immunotherapy side effects in NSCLC
A wide range of immune-related adverse events have been
reported and could involve nearly every organ system but
particularly endocrine, cutaneous, and gastrointestinal sys-
tems [67]. Furthermore, they can occur at any time, beginning
immediately after initiation of therapy until long after comple-
tion [68]. The overall incidence of irAE for patients undergo-
ing immunotherapy is about 25%. For NSCLC patients, the
most common irAEs associated with nivolumab are rash and
diarrhea, and those associated with pembrolizumab are hypo-
and hyperthyroidism [69]. The importance of early detection
of irAEs is essential to reduce associated morbidity.
Interestingly, in the phase I CA209-003 trial, in patients re-
ceiving nivolumab, overall survival was significantly
prolonged among patients with irAEs of any grade [70].
Inflammatory reactions are accompanied by irAEs and
consequently lead to an elevated FDG-avidity [71], which
might possibly lead to a misinterpretation of the respective
PET scan despite certain temporal adaptions of FDG-uptake
[72, 73]. Vice versa, this partly high FDG-avidity accompa-
nying irAEs consequently enables localization and identifica-
tion [74]; this feature gains further importance keeping in
mind the association (the occurrence of) irAEs and the thera-
peutic efficacy of immunotherapy [75, 76].
Fig. 2 Treatment response assessment in a 49-year-old patient with
NSCLC cT2b N3 M1 (TNM 8th edition) with extensive progressive
disease (rib metastasis) 2 months after initiation of combined systemic
treatment with carboplatin/pemetrexed/pembrolizumab. Consecutively,
treatment was modified to carboplatin/paclitaxel/atezolizumab/
bevacizumab; 8 weeks after initiation, a partial response was visible on
FDG PET/CT with significantly decreasing metabolic tumor volume
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Recently, the report from the EANM symposium on im-
munotherapy stated that incidental findings of irAEs should
be reported, although irAEs are not necessarily associated
with clinical features. However, detection of irAEs might lead
to clinical interventions. Newly developed signs of irAEs have
to be compared to the particular baseline scan to be able to
relate these findings to immunotherapy [6].
Particularly in NSCLC patients, the occurrence of immune-
related “sarcoid-like reactions” has to be kept in mind as these
may be misread as progressive disease since sarcoid-like re-
actions consist of lymphadenopathy and pulmonary granulo-
matosis with high FDG-avidity [77].
The possible advantage of integration of FDG PET/CT in
this scenario is the facilitation of and early detection of irAEs
consequently leading to an early intervention when necessary
and potential reversibility. An example of irAEs detected by




Beyond the mere pharmacological and clinical advances for
cancer treatment and patient care, there are, however,
dedicated technological advances regarding imaging technical
and data evaluation that will foster advances in research and
will gain further access in clinical routine. Advanced image
evaluation methods such as the extraction and analysis of
radiomic features are gaining increasing importance predom-
inantly in the research setting with the final goal to improve
the clinical decision-making by improving the diagnostic ac-
curacy of imaging beyond the mere morphological extent, but
also to provide more precise predictive/prognostic informa-
tion for clinical routine [78]. So far, however, despite increas-
ing scientific recognition, there is no high level of standardi-
zation of radiomics analysis, which hampers comparability
and high-throughput mining of quantitative image informa-
tion from routine imaging [79]. Nonetheless, more studies
correlating radiomic features with clinical outcome in
NSCLC patients also undergoing combined chemoradiother-
apy/immunotherapy were published recently underlining
radiomics as an intensive field of research in NSCLC imaging
[80, 81].
Moreover, the clinical use of artificial intelligence (AI) ap-
plications is also one of the current technological topics that
increasingly arise in scientific literature. AI might be used as a
tool to augment the clinical radiographic assessment of dis-
eases such as NSCLC by applying advanced computational
analyses in order to improve the accurate detection, but also
the disease characterization and response assessment. In the
light of evermore-increasing quantitative clinical data, but also
radiographic information including advanced radiomics anal-
yses, AI might facilitate the specific qualitative interpretation
of oncologic imaging, e.g., by automated delineation, deriving
outcome models or mere response assessment. Beyond the
mere human assessment of radiographic data, AI and machine
learning applications might potentially facilitate the interpre-
tation of large-scale information and might positively influ-
ence clinical decision-making [82–84].
Additionally, there are specific technological PET/CT ad-
vances; whole body PET imaging represents a very promising
technological advancement that might have a strong impact on
hybrid imaging, as scan times can drastically be reduced com-
pared to last-generation PET/CT scanners. Moreover, the res-
olution of range of whole-body PET scanners can also be used
for significant reductions of the necessary doses of particular
radioligands, but also for whole-body distribution and phar-
macodynamic studies. These properties might improve clini-
cal routine, but might also give new insights in research topics
such as immune-directed PET. However, only a few scanners
are available so far due to limited access and extensive need of
resources [85–88].
Novel ligands (e.g., PD1-targeted imaging)
Beyond the scope of glucose-based imaging, novel molecular
radioligands that directly target key molecules within
Fig. 3 Identification of irAEs with FDG PET/CT in a 73-year-old patient
with NSCLC cT3 N2 M0 (TNM 8th edition) who initially received con-
current chemoradiation with cisplatin/vinorelbine to a total dose of
63.6 Gy and was started on consolidation durvalumab. On follow-up
FDG PET/CT, large ground glass opacities with consecutively elevated
FDG-uptake were seen in both lungs. Moreover, newly enlarged and
FDG-avid hilar lymph nodes could be observed. In sum, the findings
were suggestive of immune-related pneumonitis and reactive lymphade-
nopathy. The patient was asymptomatic (grade 1) and as such no inter-
vention was indicated.
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immune-checkpoint pathways and immune response cascades
have emerged [89, 90]. So far, anti-PD-1 antibodies were pre-
dominantly labeled with 89Zr or 64Cu, an approach highly
feasible for in vivo imaging PD-1–expressing tumor-infiltrat-
ing lymphocytes [90]. This represents a very promising ap-
proach for noninvasive visualization and quantification of PD-
1-expression, as histochemical analyses are primarily limited
by the heterogeneous tissue expression on biopsies or single
tissue specimens [91]; this phenomenon is not restricted to
NSCLC patients, but is the case for almost any solid tumor.
Beyond the scope of preclinical trials, several studies were
already performed in humans; a study by Niemeijer et al. ap-
plied the radiolabeled anti-PD-1 monoclonal antibody 89Zr-
nivolumab in patients with advanced NSCLC. They could
demonstrate that the tumor uptake of 89Zr-nivolumab was sig-
nificantly higher in patients with immunohistochemically prov-
en PD-1-positive tumor-infiltrating immune cells compared to
those tumors classified as PD-1-negative tumors. Of note,
PD-(L)1 PET-CT could identify a highly heterogeneous tumor
uptake not just on an inter-individual but also on an intra-indi-
vidual basis. Particularly, highly diverging uptake between dif-
ferent intra-individual tumor lesions was found [92]. In further
clinical studies, high uptake on pre-treatment 89Zr-
atezolizumab PET showed a significantly stronger correlation
with the individual clinical course compared to immunohisto-
chemistry-based or RNA-sequencing-based biomarkers prior to
the initiation of PD-L1-targeted therapies [93].
With special regard to immuno-PET imaging in NSCLC
patients, several clinical trials are currently underway evaluat-
ing several novel ligands such as 89Zr-avelumab
(NCT03514719, PINNACLE), 89Zr-durvalumab (2015-
005765-23), 99mTc-anti-PD-L1 (sdAb) single-photon emis-
sion computed tomography (SPECT) (NCT02978196), or
combined imaging with 89Zr-durvalumab PET and 111In-
CD8 T cell SPECT (NCT03853187, DONAN).
Beyond PD-(L)1 imaging with PET, several further bio-
markers were deemed as potential targets for molecular imag-
ing, predominantly in preclinical settings; the protease gran-
zyme B (GZP) represents an encouraging target for immuno-
based imaging; GZP is secreted by cytotoxic CD8+ within the
process of immune-induced, caspase-dependent apoptosis.
Imaging GZP with 68Ga-NOTA-GZP in preclinical models
was already able to predict the response to immunotherapy
with a high diagnostic accuracy [94].
Moreover, attempts were made to use interferon-γ (IFNγ)
immuno-PET (89Zr-anti-IFN-γ); first studies showed that
89Zr-anti-IFN-γ PET allows imaging of activated lympho-
cytes in tumoral lesions [95]. Beyond the scope of PET imag-
ing, also promising molecular structures can be targeted using
SPECT-ligands; 99mTc-labeled interleukin-2 (99mTc-HYNIC-
IL2) allowed the visualization and quantification of tumor
infiltrating lymphocytes in the set of patients undergoing im-
munotherapy; here, 99mTc-HYNIC-IL2 SPECT could be used
as a potential imaging approach, e. g., for the differentiation of
real as opposed to pseudo-progression in patients undergoing
immunotherapy [96].
These promising efforts in both preclinical and clinical set-
ting affirm the further investigation of immuno-PET and the
comprehensive translation into clinical imaging to further im-
prove pre-treatment patient selection, response assessment,
and clinical management.
Novel treatments
In the coming years, the landscape of immunotherapeutic
options for advanced NSCLC will continue to evolve as
further drugs gain access to the market. Furthermore, it is
yet to be seen if simultaneous ICI with concurrent CRT
will further improve patient outcome. It goes without say-
ing that key players have already initiated trials, notably
PAC IF IC - 2 (NCT03519971 ) , KEYNOTE - 799
(NCT03631784), and CheckMate73L (NCT04026412) as
well as an independent study sponsored by the NCI
(NCT04092283) all assessing concurrent platinum-based
CRT with simultaneous PD1/PD-L1 inhibition [9].
Strictly hypothesis-driven, potential incorporation of dual
PET/CTs in the treatment paradigm for locally advanced
NSCLC is a possible strategy predicated on the translation
of immuno-PET into clinical practice (Fig. 4).
Fig. 4 Hypothesis driven imaging paradigm incorporating FDG-PET/CT
and immuno-PET in advanced stage NSCLC. Abbreviations: CRT, che-
moradiotherapy; ICI, immune-checkpoint inhibitor; TVD, tumor volume
delineation
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In metastatic disease, some promising drugs are on the
horizon with novel targets. In addition, adoptive cellular im-
munotherapy is a promising emerging field following the suc-
cess garnered by some of these agents in hematological ma-
lignancies [97]. Taking all these aspects into consideration,
there is a need for improved PET assessment, robust criteria,
and imaging biomarkers for longitudinal response assessment,
characterization of anti-tumor immune response, and acute/
late toxicity.
Conclusion
As novel immunotherapies arise as effective treatment options
in patients with stage III/IV NSCLC, new patterns of re-
sponse/progression and immune-related side effects occur in
clinical routine. Response criteria based on morphological
features such as RECIST 1.1 have been continuously refined
to accommodate these newly occurring, immune-related phe-
nomena. However, hybrid imaging with FDG PET/CT can
add comprehensive clinical information beyond the meremor-
phological changes during immunotherapy and radiotherapy
and for the detection of irAEs. As hybrid imaging has shown
to significantly influence clinical decision-making in several
oncological diseases, it might also allow optimization of im-
munotherapy and radiotherapy regimens and clinical manage-
ment in general. Comprehensive inclusion of PET-based re-
sponse criteria in prospective randomized-controlled trials,
but also a general harmonization within the variety of PET-
based response criteria is needed to strengthen clinical imple-
mentation and wide-spread use of hybrid imaging for response
assessment in NSCLC.
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